All In Biotech

Drug Trial Radar · NCT07826195

A Phase IIa Study Evaluating Injectable ALK-N001 in Patients With Advanced Gastrointestinal Tumors

An Open-label, Multicenter Phase IIa Study to Evaluate the Efficacy and Safety of Injectable ALK-N001 in Patients With Advanced Gastrointestinal Tumors

Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

174

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Dec 2027

Study completion Apr 2028

Sponsor

Sponsor type
Industry
First posted
Sep 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This open-label, multicenter Phase IIa study is to evaluate the efficacy and safety of injectable ALK-N001 in patients with advanced gastrointestinal tumors, with the primary objective to assess its preliminary efficacy.

Conditions

  • Advanced Gastrointestinal Tumors

Interventions

  • Injectable ALK-N001Drug

    Injectable ALK-N001 is administered intravenously every 2 weeks (Q2W; 28-day treatment cycle). Two predefined dose levels are available: 37.5 mg/m² (Dose A) and 50 mg/m² (Dose B). Enrollment or suspension of dose groups may be determined by the Safety Review Committee (SRC) based on safety, PK, PD and preliminary anti-tumor activity data.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR), assessed per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Time frame: Up to approximately 24 months from the first dose.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.